Letter to the EditorInfluenza vaccine dosages
References (2)
- et al.
Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects
Vaccine
(2007) - et al.
Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose–response study in elderly nursing-home residents and young volunteers
Vaccine
(1993)
Cited by (7)
Immunogenicity and safety of inactivated influenza vaccines in primed populations: A systematic literature review and meta-analysis
2011, VaccineCitation Excerpt :The pivotal question is whether an HI antibody titer improvement of up to ∼1.4-fold translates into a meaningful increase in clinical protection. We argued earlier that this is not likely [50]. Evidence should come from clinical exposure trials with persons of known pre-exposure HI antibody titers whose susceptibility to influenza infection is recorded, like the well-known experiments of Hobson et al., published in 1972 [51].
A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months
2010, VaccineCitation Excerpt :Beyond a certain concentration, the increase in immune response is marginal whereas, when the previously used level of antigens is low, even a marginal increase can induce a significantly higher antibody concentration [13,16]. In this regard, previous studies of elderly subjects have found that, when the antigen concentration of each of the viruses in the vaccine is changed from 10–15 μg/dose to 60 μg/dose, the GMTs of antibodies against all of the antigens only increased up to 2-fold, which cannot be considered sufficient to recommend this as a means of improving the immunogenicity of influenza vaccine [21]. We doubled the antigen concentration at each administration and reached values usually used to vaccinate children aged more than 3 years.
Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible
2009, VaccineCitation Excerpt :Intradermal influenza vaccination, using only a fifth of the normal dose, leads to similar postvaccination antibody titers and protection rates as compared to standard intramuscular vaccination in immunocompromized patients. Since there is a dose–response relation between the amount of antigen used and the subsequent serologic response, this indicates that intradermal vaccination is more efficient in inducing antibody responses than intramuscular vaccination [17,18]. This principle was recently proven to be valid in a clinical study [36].
Seasonal inactivated influenza virus vaccines
2008, VaccineCitation Excerpt :The same vaccine given as 15–135 μg HA to elderly persons increased serum HAI titers 1.1–5.3-fold and neut titers 1.2–6.1-fold [19]. As noted recently, a sigmoid curve with a plateau seems likely for serum anti-HA responses to increasing dosages of HA; however, the variables that define the maximal response plateau for different vaccines in different populations using different antibody test procedures have not been identified [20]. While such data could aid our understanding, it is more important to determine the consistency of increasing protection against influenza with increasing anti-HA antibody titers.
Novel strategies for improved vaccines for the elderly: The example of influenza
2012, Immunosenescence